The stock of BioNTech SE ADR (NASDAQ: BNTX) has decreased by -0.74 when compared to last closing price of 112.76. Despite this, the company has experienced a -8.89% fall in its stock price over the last five trading sessions. zacks.com reported 2025-01-17 that The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is It Worth Investing in BioNTech SE ADR (NASDAQ: BNTX) Right Now?
Company’s 36-month beta value is 0.17.Analysts have differing opinions on the stock, with 12 analysts rating it as a “buy,” 4 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BNTX is 239.44M, and currently, short sellers hold a 1.07% ratio of that floaft. The average trading volume of BNTX on January 20, 2025 was 837.66K shares.
BNTX’s Market Performance
The stock of BioNTech SE ADR (BNTX) has seen a -8.89% decrease in the past week, with a -2.00% drop in the past month, and a -4.93% fall in the past quarter. The volatility ratio for the week is 3.70%, and the volatility levels for the past 30 days are at 3.47% for BNTX. The simple moving average for the last 20 days is -2.91% for BNTX stock, with a simple moving average of 11.66% for the last 200 days.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Truist repeating the rating for BNTX by listing it as a “Buy.” The predicted price for BNTX in the upcoming period, according to Truist is $172 based on the research report published on January 10, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $170. The rating they have provided for BNTX stocks is “Overweight” according to the report published on December 11th, 2024.
BNTX Trading at -1.81% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.88% of loss for the given period.
Volatility was left at 3.47%, however, over the last 30 days, the volatility rate increased by 3.70%, as shares sank -4.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.72% upper at present.
During the last 5 trading sessions, BNTX fell by -8.89%, which changed the moving average for the period of 200-days by +22.29% in comparison to the 20-day moving average, which settled at $115.28. In addition, BioNTech SE ADR saw -1.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTX starting from ATHOS KG, who proposed sale 4,983 shares at the price of $120.69 back on Dec 13 ’24. After this action, ATHOS KG now owns shares of BioNTech SE ADR, valued at $601,398 using the latest closing price.
ATHOS KG, the 10% Owner of BioNTech SE ADR, proposed sale 22,450 shares at $116.85 during a trade that took place back on Dec 11 ’24, which means that ATHOS KG is holding shares at $2,623,283 based on the most recent closing price.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.84 for the gross margin
The net margin for BioNTech SE ADR stands at -0.16. The total capital return value is set at -0.03. Equity return is now at value -2.37, with -2.07 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 6.39. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17.5.
Currently, EBITDA for the company is 1.09 billion with net debt to EBITDA at 104.32. When we switch over and look at the enterprise to sales, we see a ratio of 5.77. The receivables turnover for the company is 2.52for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In a nutshell, BioNTech SE ADR (BNTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
